Humacyte Stock Revenue
| HUMA Stock | USD 4.51 0.14 3.01% |
Humacyte fundamentals help investors to digest information that contributes to Humacyte's financial success or failures. It also enables traders to predict the movement of Humacyte Stock. The fundamental analysis module provides a way to measure Humacyte's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Humacyte stock.
| Last Reported | Projected for Next Year |
Humacyte | Revenue |
Humacyte Company Revenue Analysis
Humacyte's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Humacyte
Projected quarterly revenue analysis of Humacyte provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Humacyte match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Humacyte's stock price.
Humacyte Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Humacyte is extremely important. It helps to project a fair market value of Humacyte Stock properly, considering its historical fundamentals such as Revenue. Since Humacyte's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Humacyte's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Humacyte's interrelated accounts and indicators.
| 0.76 | 0.13 | 0.42 | 0.79 | 0.75 | ||
| 0.76 | 0.56 | 0.89 | 0.98 | 0.99 | ||
| 0.13 | 0.56 | 0.82 | 0.61 | 0.58 | ||
| 0.42 | 0.89 | 0.82 | 0.88 | 0.88 | ||
| 0.79 | 0.98 | 0.61 | 0.88 | 0.99 | ||
| 0.75 | 0.99 | 0.58 | 0.88 | 0.99 |
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Humacyte Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Humacyte reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Humacyte Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Humacyte's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Humacyte could also be used in its relative valuation, which is a method of valuing Humacyte by comparing valuation metrics of similar companies.Humacyte is currently under evaluation in revenue category among its peers.
Humacyte ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Humacyte's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Humacyte's managers, analysts, and investors.Environmental | Governance | Social |
Humacyte Institutional Holders
Institutional Holdings refers to the ownership stake in Humacyte that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Humacyte's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Humacyte's value.| Shares | Marshall Wace Asset Management Ltd | 2024-09-30 | 584.6 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 559.3 K | Susquehanna International Group, Llp | 2024-09-30 | 557 K | Monashee Investment Management Llc | 2024-09-30 | 535 K | Lpl Financial Corp | 2024-09-30 | 512 K | Nuveen Asset Management, Llc | 2024-09-30 | 395.1 K | Private Advisor Group, Llc | 2024-09-30 | 373.1 K | Jump Financial Llc | 2024-09-30 | 327.6 K | Wellington Management Company Llp | 2024-09-30 | 254.4 K | Blackrock Inc | 2024-06-30 | 7.1 M | Vanguard Group Inc | 2024-09-30 | 5.1 M |
Humacyte Fundamentals
| Return On Equity | -8.51 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 576.99 M | ||||
| Shares Outstanding | 128.67 M | ||||
| Shares Owned By Insiders | 26.87 % | ||||
| Shares Owned By Institutions | 30.01 % | ||||
| Number Of Shares Shorted | 21.96 M | ||||
| Price To Earning | 18.04 X | ||||
| Price To Book | 30.28 X | ||||
| Price To Sales | 153.91 X | ||||
| Gross Profit | 1.56 M | ||||
| EBITDA | (96.46 M) | ||||
| Net Income | (110.78 M) | ||||
| Cash And Equivalents | 189.04 M | ||||
| Cash Per Share | 1.84 X | ||||
| Total Debt | 58.11 M | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 17.46 X | ||||
| Book Value Per Share | (0.53) X | ||||
| Cash Flow From Operations | (73.31 M) | ||||
| Short Ratio | 6.37 X | ||||
| Earnings Per Share | (1.34) X | ||||
| Target Price | 13.71 | ||||
| Number Of Employees | 183 | ||||
| Beta | 1.47 | ||||
| Market Capitalization | 580.29 M | ||||
| Total Asset | 128.22 M | ||||
| Retained Earnings | (537.31 M) | ||||
| Working Capital | 64.83 M | ||||
| Net Asset | 128.22 M |
About Humacyte Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Humacyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Humacyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Humacyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Humacyte is a strong investment it is important to analyze Humacyte's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Humacyte's future performance. For an informed investment choice regarding Humacyte Stock, refer to the following important reports:Check out Humacyte Piotroski F Score and Humacyte Altman Z Score analysis. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. If investors know Humacyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Humacyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Quarterly Revenue Growth (1.00) | Return On Assets (0.53) | Return On Equity (8.51) |
The market value of Humacyte is measured differently than its book value, which is the value of Humacyte that is recorded on the company's balance sheet. Investors also form their own opinion of Humacyte's value that differs from its market value or its book value, called intrinsic value, which is Humacyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Humacyte's market value can be influenced by many factors that don't directly affect Humacyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.